Global Drug-Eluting Stent Market

Drug-Eluting Stent Comprehensive Study by Type (Cobalt-chromium alloy, Magnesium alloy, Tyrosine polycarbonate, Nitinol, Platinum chromium alloy, Stainless steel, Others), Application (Coronary Heart Disease, Coronary Arteries, Peripheral, Others), End Users (Hospitals, Surgical centres, Special Cardiac centres), Characteristics (Bioactive, Bio-resorbable, Self-expanding) Players and Region - Global Market Outlook to 2027

Drug-Eluting Stent Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
Drug-eluting stents are material inserted in body coated with medication that is slowly released at the site of action to prevent the growth of scar tissue in the artery lining. It facilitates good blood flow and smooth opening in the artery .it reliefs against chest pain and various cardiac disorders they are a safest and effective medication for many disorders. There are very few side effects and disadvantages of this device and rarely heart attacks and strokes occur.This device is also commonly known as DES. Various material like metals ,alloys are used for this devices .

Influencing Trend:
Growing Technological Improvements and Highly Used As Safe And Effective In The Results

Market Growth Drivers:
Increasing Cardiac Surgeries and Growing Population Of Cardiac Disorders

Challenges:
Various Contradictions May Occur After Surgery

The key Players profiled in the report are Terumo Corporation (Japan), B.Braun (Germany), Promed medical (United Arab Emirates), Boston Scientific (United States), Abbott Vascular (United States), Relisys Medical (India), Medtronic Vascular (Ireland), Sinomedical (China), Lepu Medical (China) and BIOTRONIK (Germany).

Report Objectives / Segmentation Covered

By Type
  • Cobalt-chromium alloy
  • Magnesium alloy
  • Tyrosine polycarbonate
  • Nitinol
  • Platinum chromium alloy
  • Stainless steel
  • Others
By Application
  • Coronary Heart Disease
  • Coronary Arteries
  • Peripheral
  • Others
By End Users
  • Hospitals
  • Surgical centres
  • Special Cardiac centres

By Characteristics
  • Bioactive
  • Bio-resorbable
  • Self-expanding

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Cardiac Surgeries
      • 3.2.2. Growing Population Of Cardiac Disorders
    • 3.3. Market Challenges
      • 3.3.1. Various Contradictions May Occur After Surgery
    • 3.4. Market Trends
      • 3.4.1. Growing Technological Improvements
      • 3.4.2. Highly Used As Safe And Effective In The Results
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug-Eluting Stent, by Type, Application, End Users, Characteristics and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Drug-Eluting Stent (Value)
      • 5.2.1. Global Drug-Eluting Stent by: Type (Value)
        • 5.2.1.1. Cobalt-chromium alloy
        • 5.2.1.2. Magnesium alloy
        • 5.2.1.3. Tyrosine polycarbonate
        • 5.2.1.4. Nitinol
        • 5.2.1.5. Platinum chromium alloy
        • 5.2.1.6. Stainless steel
        • 5.2.1.7. Others
      • 5.2.2. Global Drug-Eluting Stent by: Application (Value)
        • 5.2.2.1. Coronary Heart Disease
        • 5.2.2.2. Coronary Arteries
        • 5.2.2.3. Peripheral
        • 5.2.2.4. Others
      • 5.2.3. Global Drug-Eluting Stent by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Surgical centres
        • 5.2.3.3. Special Cardiac centres
      • 5.2.4. Global Drug-Eluting Stent Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Drug-Eluting Stent (Volume)
      • 5.3.1. Global Drug-Eluting Stent by: Type (Volume)
        • 5.3.1.1. Cobalt-chromium alloy
        • 5.3.1.2. Magnesium alloy
        • 5.3.1.3. Tyrosine polycarbonate
        • 5.3.1.4. Nitinol
        • 5.3.1.5. Platinum chromium alloy
        • 5.3.1.6. Stainless steel
        • 5.3.1.7. Others
      • 5.3.2. Global Drug-Eluting Stent by: Application (Volume)
        • 5.3.2.1. Coronary Heart Disease
        • 5.3.2.2. Coronary Arteries
        • 5.3.2.3. Peripheral
        • 5.3.2.4. Others
      • 5.3.3. Global Drug-Eluting Stent by: End Users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Surgical centres
        • 5.3.3.3. Special Cardiac centres
      • 5.3.4. Global Drug-Eluting Stent Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Drug-Eluting Stent (Price)
      • 5.4.1. Global Drug-Eluting Stent by: Type (Price)
  • 6. Drug-Eluting Stent: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Terumo Corporation (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. B.Braun (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Promed medical (United Arab Emirates)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boston Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Vascular (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Relisys Medical (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medtronic Vascular (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sinomedical (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lepu Medical (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BIOTRONIK (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drug-Eluting Stent Sale, by Type, Application, End Users, Characteristics and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Drug-Eluting Stent (Value)
      • 7.2.1. Global Drug-Eluting Stent by: Type (Value)
        • 7.2.1.1. Cobalt-chromium alloy
        • 7.2.1.2. Magnesium alloy
        • 7.2.1.3. Tyrosine polycarbonate
        • 7.2.1.4. Nitinol
        • 7.2.1.5. Platinum chromium alloy
        • 7.2.1.6. Stainless steel
        • 7.2.1.7. Others
      • 7.2.2. Global Drug-Eluting Stent by: Application (Value)
        • 7.2.2.1. Coronary Heart Disease
        • 7.2.2.2. Coronary Arteries
        • 7.2.2.3. Peripheral
        • 7.2.2.4. Others
      • 7.2.3. Global Drug-Eluting Stent by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Surgical centres
        • 7.2.3.3. Special Cardiac centres
      • 7.2.4. Global Drug-Eluting Stent Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Drug-Eluting Stent (Volume)
      • 7.3.1. Global Drug-Eluting Stent by: Type (Volume)
        • 7.3.1.1. Cobalt-chromium alloy
        • 7.3.1.2. Magnesium alloy
        • 7.3.1.3. Tyrosine polycarbonate
        • 7.3.1.4. Nitinol
        • 7.3.1.5. Platinum chromium alloy
        • 7.3.1.6. Stainless steel
        • 7.3.1.7. Others
      • 7.3.2. Global Drug-Eluting Stent by: Application (Volume)
        • 7.3.2.1. Coronary Heart Disease
        • 7.3.2.2. Coronary Arteries
        • 7.3.2.3. Peripheral
        • 7.3.2.4. Others
      • 7.3.3. Global Drug-Eluting Stent by: End Users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Surgical centres
        • 7.3.3.3. Special Cardiac centres
      • 7.3.4. Global Drug-Eluting Stent Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Drug-Eluting Stent (Price)
      • 7.4.1. Global Drug-Eluting Stent by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug-Eluting Stent: by Type(USD Million)
  • Table 2. Drug-Eluting Stent Cobalt-chromium alloy , by Region USD Million (2016-2021)
  • Table 3. Drug-Eluting Stent Magnesium alloy , by Region USD Million (2016-2021)
  • Table 4. Drug-Eluting Stent Tyrosine polycarbonate , by Region USD Million (2016-2021)
  • Table 5. Drug-Eluting Stent Nitinol , by Region USD Million (2016-2021)
  • Table 6. Drug-Eluting Stent Platinum chromium alloy , by Region USD Million (2016-2021)
  • Table 7. Drug-Eluting Stent Stainless steel , by Region USD Million (2016-2021)
  • Table 8. Drug-Eluting Stent Others , by Region USD Million (2016-2021)
  • Table 9. Drug-Eluting Stent: by Application(USD Million)
  • Table 10. Drug-Eluting Stent Coronary Heart Disease , by Region USD Million (2016-2021)
  • Table 11. Drug-Eluting Stent Coronary Arteries , by Region USD Million (2016-2021)
  • Table 12. Drug-Eluting Stent Peripheral , by Region USD Million (2016-2021)
  • Table 13. Drug-Eluting Stent Others , by Region USD Million (2016-2021)
  • Table 14. Drug-Eluting Stent: by End Users(USD Million)
  • Table 15. Drug-Eluting Stent Hospitals , by Region USD Million (2016-2021)
  • Table 16. Drug-Eluting Stent Surgical centres , by Region USD Million (2016-2021)
  • Table 17. Drug-Eluting Stent Special Cardiac centres , by Region USD Million (2016-2021)
  • Table 18. South America Drug-Eluting Stent, by Country USD Million (2016-2021)
  • Table 19. South America Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 20. South America Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 21. South America Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 22. South America Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 23. Brazil Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 24. Brazil Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 25. Brazil Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 26. Brazil Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 27. Argentina Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 28. Argentina Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 29. Argentina Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 30. Argentina Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 31. Rest of South America Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 32. Rest of South America Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 33. Rest of South America Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 34. Rest of South America Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 35. Asia Pacific Drug-Eluting Stent, by Country USD Million (2016-2021)
  • Table 36. Asia Pacific Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 37. Asia Pacific Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 38. Asia Pacific Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 39. Asia Pacific Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 40. China Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 41. China Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 42. China Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 43. China Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 44. Japan Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 45. Japan Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 46. Japan Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 47. Japan Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 48. India Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 49. India Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 50. India Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 51. India Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 52. South Korea Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 53. South Korea Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 54. South Korea Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 55. South Korea Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 56. Taiwan Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 57. Taiwan Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 58. Taiwan Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 59. Taiwan Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 60. Australia Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 61. Australia Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 62. Australia Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 63. Australia Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 68. Europe Drug-Eluting Stent, by Country USD Million (2016-2021)
  • Table 69. Europe Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 70. Europe Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 71. Europe Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 72. Europe Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 73. Germany Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 74. Germany Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 75. Germany Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 76. Germany Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 77. France Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 78. France Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 79. France Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 80. France Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 81. Italy Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 82. Italy Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 83. Italy Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 84. Italy Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 85. United Kingdom Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 86. United Kingdom Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 87. United Kingdom Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 88. United Kingdom Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 89. Netherlands Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 90. Netherlands Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 91. Netherlands Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 92. Netherlands Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 93. Rest of Europe Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 94. Rest of Europe Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 95. Rest of Europe Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 96. Rest of Europe Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 97. MEA Drug-Eluting Stent, by Country USD Million (2016-2021)
  • Table 98. MEA Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 99. MEA Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 100. MEA Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 101. MEA Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 102. Middle East Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 103. Middle East Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 104. Middle East Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 105. Middle East Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 106. Africa Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 107. Africa Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 108. Africa Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 109. Africa Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 110. North America Drug-Eluting Stent, by Country USD Million (2016-2021)
  • Table 111. North America Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 112. North America Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 113. North America Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 114. North America Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 115. United States Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 116. United States Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 117. United States Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 118. United States Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 119. Canada Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 120. Canada Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 121. Canada Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 122. Canada Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 123. Mexico Drug-Eluting Stent, by Type USD Million (2016-2021)
  • Table 124. Mexico Drug-Eluting Stent, by Application USD Million (2016-2021)
  • Table 125. Mexico Drug-Eluting Stent, by End Users USD Million (2016-2021)
  • Table 126. Mexico Drug-Eluting Stent, by Characteristics USD Million (2016-2021)
  • Table 127. Drug-Eluting Stent Sales: by Type(K Unit)
  • Table 128. Drug-Eluting Stent Sales Cobalt-chromium alloy , by Region K Unit (2016-2021)
  • Table 129. Drug-Eluting Stent Sales Magnesium alloy , by Region K Unit (2016-2021)
  • Table 130. Drug-Eluting Stent Sales Tyrosine polycarbonate , by Region K Unit (2016-2021)
  • Table 131. Drug-Eluting Stent Sales Nitinol , by Region K Unit (2016-2021)
  • Table 132. Drug-Eluting Stent Sales Platinum chromium alloy , by Region K Unit (2016-2021)
  • Table 133. Drug-Eluting Stent Sales Stainless steel , by Region K Unit (2016-2021)
  • Table 134. Drug-Eluting Stent Sales Others , by Region K Unit (2016-2021)
  • Table 135. Drug-Eluting Stent Sales: by Application(K Unit)
  • Table 136. Drug-Eluting Stent Sales Coronary Heart Disease , by Region K Unit (2016-2021)
  • Table 137. Drug-Eluting Stent Sales Coronary Arteries , by Region K Unit (2016-2021)
  • Table 138. Drug-Eluting Stent Sales Peripheral , by Region K Unit (2016-2021)
  • Table 139. Drug-Eluting Stent Sales Others , by Region K Unit (2016-2021)
  • Table 140. Drug-Eluting Stent Sales: by End Users(K Unit)
  • Table 141. Drug-Eluting Stent Sales Hospitals , by Region K Unit (2016-2021)
  • Table 142. Drug-Eluting Stent Sales Surgical centres , by Region K Unit (2016-2021)
  • Table 143. Drug-Eluting Stent Sales Special Cardiac centres , by Region K Unit (2016-2021)
  • Table 144. South America Drug-Eluting Stent Sales, by Country K Unit (2016-2021)
  • Table 145. South America Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 146. South America Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 147. South America Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 148. South America Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 149. Brazil Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 150. Brazil Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 151. Brazil Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 152. Brazil Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 153. Argentina Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 154. Argentina Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 155. Argentina Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 156. Argentina Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 157. Rest of South America Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 158. Rest of South America Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 159. Rest of South America Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 160. Rest of South America Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 161. Asia Pacific Drug-Eluting Stent Sales, by Country K Unit (2016-2021)
  • Table 162. Asia Pacific Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 163. Asia Pacific Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 164. Asia Pacific Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 165. Asia Pacific Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 166. China Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 167. China Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 168. China Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 169. China Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 170. Japan Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 171. Japan Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 172. Japan Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 173. Japan Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 174. India Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 175. India Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 176. India Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 177. India Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 178. South Korea Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 179. South Korea Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 180. South Korea Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 181. South Korea Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 182. Taiwan Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 183. Taiwan Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 184. Taiwan Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 185. Taiwan Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 186. Australia Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 187. Australia Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 188. Australia Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 189. Australia Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 190. Rest of Asia-Pacific Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 191. Rest of Asia-Pacific Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 192. Rest of Asia-Pacific Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 193. Rest of Asia-Pacific Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 194. Europe Drug-Eluting Stent Sales, by Country K Unit (2016-2021)
  • Table 195. Europe Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 196. Europe Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 197. Europe Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 198. Europe Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 199. Germany Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 200. Germany Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 201. Germany Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 202. Germany Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 203. France Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 204. France Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 205. France Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 206. France Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 207. Italy Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 208. Italy Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 209. Italy Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 210. Italy Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 211. United Kingdom Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 212. United Kingdom Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 213. United Kingdom Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 214. United Kingdom Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 215. Netherlands Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 216. Netherlands Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 217. Netherlands Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 218. Netherlands Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 219. Rest of Europe Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 220. Rest of Europe Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 221. Rest of Europe Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 222. Rest of Europe Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 223. MEA Drug-Eluting Stent Sales, by Country K Unit (2016-2021)
  • Table 224. MEA Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 225. MEA Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 226. MEA Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 227. MEA Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 228. Middle East Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 229. Middle East Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 230. Middle East Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 231. Middle East Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 232. Africa Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 233. Africa Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 234. Africa Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 235. Africa Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 236. North America Drug-Eluting Stent Sales, by Country K Unit (2016-2021)
  • Table 237. North America Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 238. North America Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 239. North America Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 240. North America Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 241. United States Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 242. United States Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 243. United States Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 244. United States Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 245. Canada Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 246. Canada Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 247. Canada Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 248. Canada Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 249. Mexico Drug-Eluting Stent Sales, by Type K Unit (2016-2021)
  • Table 250. Mexico Drug-Eluting Stent Sales, by Application K Unit (2016-2021)
  • Table 251. Mexico Drug-Eluting Stent Sales, by End Users K Unit (2016-2021)
  • Table 252. Mexico Drug-Eluting Stent Sales, by Characteristics K Unit (2016-2021)
  • Table 253. Drug-Eluting Stent: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Drug-Eluting Stent: by Type(USD Million)
  • Table 265. Drug-Eluting Stent Cobalt-chromium alloy , by Region USD Million (2022-2027)
  • Table 266. Drug-Eluting Stent Magnesium alloy , by Region USD Million (2022-2027)
  • Table 267. Drug-Eluting Stent Tyrosine polycarbonate , by Region USD Million (2022-2027)
  • Table 268. Drug-Eluting Stent Nitinol , by Region USD Million (2022-2027)
  • Table 269. Drug-Eluting Stent Platinum chromium alloy , by Region USD Million (2022-2027)
  • Table 270. Drug-Eluting Stent Stainless steel , by Region USD Million (2022-2027)
  • Table 271. Drug-Eluting Stent Others , by Region USD Million (2022-2027)
  • Table 272. Drug-Eluting Stent: by Application(USD Million)
  • Table 273. Drug-Eluting Stent Coronary Heart Disease , by Region USD Million (2022-2027)
  • Table 274. Drug-Eluting Stent Coronary Arteries , by Region USD Million (2022-2027)
  • Table 275. Drug-Eluting Stent Peripheral , by Region USD Million (2022-2027)
  • Table 276. Drug-Eluting Stent Others , by Region USD Million (2022-2027)
  • Table 277. Drug-Eluting Stent: by End Users(USD Million)
  • Table 278. Drug-Eluting Stent Hospitals , by Region USD Million (2022-2027)
  • Table 279. Drug-Eluting Stent Surgical centres , by Region USD Million (2022-2027)
  • Table 280. Drug-Eluting Stent Special Cardiac centres , by Region USD Million (2022-2027)
  • Table 281. South America Drug-Eluting Stent, by Country USD Million (2022-2027)
  • Table 282. South America Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 283. South America Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 284. South America Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 285. South America Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 286. Brazil Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 287. Brazil Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 288. Brazil Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 289. Brazil Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 290. Argentina Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 291. Argentina Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 292. Argentina Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 293. Argentina Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 294. Rest of South America Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 295. Rest of South America Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 296. Rest of South America Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 297. Rest of South America Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 298. Asia Pacific Drug-Eluting Stent, by Country USD Million (2022-2027)
  • Table 299. Asia Pacific Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 300. Asia Pacific Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 301. Asia Pacific Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 302. Asia Pacific Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 303. China Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 304. China Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 305. China Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 306. China Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 307. Japan Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 308. Japan Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 309. Japan Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 310. Japan Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 311. India Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 312. India Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 313. India Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 314. India Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 315. South Korea Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 316. South Korea Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 317. South Korea Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 318. South Korea Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 319. Taiwan Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 320. Taiwan Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 321. Taiwan Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 322. Taiwan Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 323. Australia Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 324. Australia Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 325. Australia Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 326. Australia Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 327. Rest of Asia-Pacific Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 328. Rest of Asia-Pacific Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 329. Rest of Asia-Pacific Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 330. Rest of Asia-Pacific Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 331. Europe Drug-Eluting Stent, by Country USD Million (2022-2027)
  • Table 332. Europe Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 333. Europe Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 334. Europe Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 335. Europe Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 336. Germany Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 337. Germany Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 338. Germany Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 339. Germany Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 340. France Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 341. France Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 342. France Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 343. France Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 344. Italy Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 345. Italy Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 346. Italy Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 347. Italy Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 348. United Kingdom Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 349. United Kingdom Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 350. United Kingdom Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 351. United Kingdom Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 352. Netherlands Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 353. Netherlands Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 354. Netherlands Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 355. Netherlands Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 356. Rest of Europe Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 357. Rest of Europe Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 358. Rest of Europe Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 359. Rest of Europe Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 360. MEA Drug-Eluting Stent, by Country USD Million (2022-2027)
  • Table 361. MEA Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 362. MEA Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 363. MEA Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 364. MEA Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 365. Middle East Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 366. Middle East Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 367. Middle East Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 368. Middle East Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 369. Africa Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 370. Africa Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 371. Africa Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 372. Africa Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 373. North America Drug-Eluting Stent, by Country USD Million (2022-2027)
  • Table 374. North America Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 375. North America Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 376. North America Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 377. North America Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 378. United States Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 379. United States Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 380. United States Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 381. United States Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 382. Canada Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 383. Canada Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 384. Canada Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 385. Canada Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 386. Mexico Drug-Eluting Stent, by Type USD Million (2022-2027)
  • Table 387. Mexico Drug-Eluting Stent, by Application USD Million (2022-2027)
  • Table 388. Mexico Drug-Eluting Stent, by End Users USD Million (2022-2027)
  • Table 389. Mexico Drug-Eluting Stent, by Characteristics USD Million (2022-2027)
  • Table 390. Drug-Eluting Stent Sales: by Type(K Unit)
  • Table 391. Drug-Eluting Stent Sales Cobalt-chromium alloy , by Region K Unit (2022-2027)
  • Table 392. Drug-Eluting Stent Sales Magnesium alloy , by Region K Unit (2022-2027)
  • Table 393. Drug-Eluting Stent Sales Tyrosine polycarbonate , by Region K Unit (2022-2027)
  • Table 394. Drug-Eluting Stent Sales Nitinol , by Region K Unit (2022-2027)
  • Table 395. Drug-Eluting Stent Sales Platinum chromium alloy , by Region K Unit (2022-2027)
  • Table 396. Drug-Eluting Stent Sales Stainless steel , by Region K Unit (2022-2027)
  • Table 397. Drug-Eluting Stent Sales Others , by Region K Unit (2022-2027)
  • Table 398. Drug-Eluting Stent Sales: by Application(K Unit)
  • Table 399. Drug-Eluting Stent Sales Coronary Heart Disease , by Region K Unit (2022-2027)
  • Table 400. Drug-Eluting Stent Sales Coronary Arteries , by Region K Unit (2022-2027)
  • Table 401. Drug-Eluting Stent Sales Peripheral , by Region K Unit (2022-2027)
  • Table 402. Drug-Eluting Stent Sales Others , by Region K Unit (2022-2027)
  • Table 403. Drug-Eluting Stent Sales: by End Users(K Unit)
  • Table 404. Drug-Eluting Stent Sales Hospitals , by Region K Unit (2022-2027)
  • Table 405. Drug-Eluting Stent Sales Surgical centres , by Region K Unit (2022-2027)
  • Table 406. Drug-Eluting Stent Sales Special Cardiac centres , by Region K Unit (2022-2027)
  • Table 407. South America Drug-Eluting Stent Sales, by Country K Unit (2022-2027)
  • Table 408. South America Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 409. South America Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 410. South America Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 411. South America Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 412. Brazil Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 413. Brazil Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 414. Brazil Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 415. Brazil Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 416. Argentina Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 417. Argentina Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 418. Argentina Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 419. Argentina Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 420. Rest of South America Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 421. Rest of South America Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 422. Rest of South America Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 423. Rest of South America Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 424. Asia Pacific Drug-Eluting Stent Sales, by Country K Unit (2022-2027)
  • Table 425. Asia Pacific Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 426. Asia Pacific Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 427. Asia Pacific Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 428. Asia Pacific Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 429. China Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 430. China Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 431. China Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 432. China Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 433. Japan Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 434. Japan Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 435. Japan Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 436. Japan Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 437. India Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 438. India Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 439. India Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 440. India Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 441. South Korea Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 442. South Korea Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 443. South Korea Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 444. South Korea Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 445. Taiwan Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 446. Taiwan Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 447. Taiwan Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 448. Taiwan Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 449. Australia Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 450. Australia Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 451. Australia Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 452. Australia Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 453. Rest of Asia-Pacific Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 454. Rest of Asia-Pacific Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 455. Rest of Asia-Pacific Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 456. Rest of Asia-Pacific Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 457. Europe Drug-Eluting Stent Sales, by Country K Unit (2022-2027)
  • Table 458. Europe Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 459. Europe Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 460. Europe Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 461. Europe Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 462. Germany Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 463. Germany Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 464. Germany Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 465. Germany Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 466. France Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 467. France Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 468. France Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 469. France Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 470. Italy Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 471. Italy Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 472. Italy Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 473. Italy Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 474. United Kingdom Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 475. United Kingdom Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 476. United Kingdom Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 477. United Kingdom Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 478. Netherlands Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 479. Netherlands Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 480. Netherlands Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 481. Netherlands Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 482. Rest of Europe Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 483. Rest of Europe Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 484. Rest of Europe Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 485. Rest of Europe Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 486. MEA Drug-Eluting Stent Sales, by Country K Unit (2022-2027)
  • Table 487. MEA Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 488. MEA Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 489. MEA Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 490. MEA Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 491. Middle East Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 492. Middle East Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 493. Middle East Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 494. Middle East Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 495. Africa Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 496. Africa Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 497. Africa Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 498. Africa Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 499. North America Drug-Eluting Stent Sales, by Country K Unit (2022-2027)
  • Table 500. North America Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 501. North America Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 502. North America Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 503. North America Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 504. United States Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 505. United States Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 506. United States Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 507. United States Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 508. Canada Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 509. Canada Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 510. Canada Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 511. Canada Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 512. Mexico Drug-Eluting Stent Sales, by Type K Unit (2022-2027)
  • Table 513. Mexico Drug-Eluting Stent Sales, by Application K Unit (2022-2027)
  • Table 514. Mexico Drug-Eluting Stent Sales, by End Users K Unit (2022-2027)
  • Table 515. Mexico Drug-Eluting Stent Sales, by Characteristics K Unit (2022-2027)
  • Table 516. Drug-Eluting Stent: by Type(USD/Units)
  • Table 517. Research Programs/Design for This Report
  • Table 518. Key Data Information from Secondary Sources
  • Table 519. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug-Eluting Stent: by Type USD Million (2016-2021)
  • Figure 5. Global Drug-Eluting Stent: by Application USD Million (2016-2021)
  • Figure 6. Global Drug-Eluting Stent: by End Users USD Million (2016-2021)
  • Figure 7. South America Drug-Eluting Stent Share (%), by Country
  • Figure 8. Asia Pacific Drug-Eluting Stent Share (%), by Country
  • Figure 9. Europe Drug-Eluting Stent Share (%), by Country
  • Figure 10. MEA Drug-Eluting Stent Share (%), by Country
  • Figure 11. North America Drug-Eluting Stent Share (%), by Country
  • Figure 12. Global Drug-Eluting Stent: by Type K Unit (2016-2021)
  • Figure 13. Global Drug-Eluting Stent: by Application K Unit (2016-2021)
  • Figure 14. Global Drug-Eluting Stent: by End Users K Unit (2016-2021)
  • Figure 15. South America Drug-Eluting Stent Share (%), by Country
  • Figure 16. Asia Pacific Drug-Eluting Stent Share (%), by Country
  • Figure 17. Europe Drug-Eluting Stent Share (%), by Country
  • Figure 18. MEA Drug-Eluting Stent Share (%), by Country
  • Figure 19. North America Drug-Eluting Stent Share (%), by Country
  • Figure 20. Global Drug-Eluting Stent: by Type USD/Units (2016-2021)
  • Figure 21. Global Drug-Eluting Stent share by Players 2021 (%)
  • Figure 22. Global Drug-Eluting Stent share by Players (Top 3) 2021(%)
  • Figure 23. Global Drug-Eluting Stent share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Terumo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Terumo Corporation (Japan) Revenue: by Geography 2021
  • Figure 27. B.Braun (Germany) Revenue, Net Income and Gross profit
  • Figure 28. B.Braun (Germany) Revenue: by Geography 2021
  • Figure 29. Promed medical (United Arab Emirates) Revenue, Net Income and Gross profit
  • Figure 30. Promed medical (United Arab Emirates) Revenue: by Geography 2021
  • Figure 31. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 32. Boston Scientific (United States) Revenue: by Geography 2021
  • Figure 33. Abbott Vascular (United States) Revenue, Net Income and Gross profit
  • Figure 34. Abbott Vascular (United States) Revenue: by Geography 2021
  • Figure 35. Relisys Medical (India) Revenue, Net Income and Gross profit
  • Figure 36. Relisys Medical (India) Revenue: by Geography 2021
  • Figure 37. Medtronic Vascular (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. Medtronic Vascular (Ireland) Revenue: by Geography 2021
  • Figure 39. Sinomedical (China) Revenue, Net Income and Gross profit
  • Figure 40. Sinomedical (China) Revenue: by Geography 2021
  • Figure 41. Lepu Medical (China) Revenue, Net Income and Gross profit
  • Figure 42. Lepu Medical (China) Revenue: by Geography 2021
  • Figure 43. BIOTRONIK (Germany) Revenue, Net Income and Gross profit
  • Figure 44. BIOTRONIK (Germany) Revenue: by Geography 2021
  • Figure 45. Global Drug-Eluting Stent: by Type USD Million (2022-2027)
  • Figure 46. Global Drug-Eluting Stent: by Application USD Million (2022-2027)
  • Figure 47. Global Drug-Eluting Stent: by End Users USD Million (2022-2027)
  • Figure 48. South America Drug-Eluting Stent Share (%), by Country
  • Figure 49. Asia Pacific Drug-Eluting Stent Share (%), by Country
  • Figure 50. Europe Drug-Eluting Stent Share (%), by Country
  • Figure 51. MEA Drug-Eluting Stent Share (%), by Country
  • Figure 52. North America Drug-Eluting Stent Share (%), by Country
  • Figure 53. Global Drug-Eluting Stent: by Type K Unit (2022-2027)
  • Figure 54. Global Drug-Eluting Stent: by Application K Unit (2022-2027)
  • Figure 55. Global Drug-Eluting Stent: by End Users K Unit (2022-2027)
  • Figure 56. South America Drug-Eluting Stent Share (%), by Country
  • Figure 57. Asia Pacific Drug-Eluting Stent Share (%), by Country
  • Figure 58. Europe Drug-Eluting Stent Share (%), by Country
  • Figure 59. MEA Drug-Eluting Stent Share (%), by Country
  • Figure 60. North America Drug-Eluting Stent Share (%), by Country
  • Figure 61. Global Drug-Eluting Stent: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Terumo Corporation (Japan)
  • B.Braun (Germany)
  • Promed medical (United Arab Emirates)
  • Boston Scientific (United States)
  • Abbott Vascular (United States)
  • Relisys Medical (India)
  • Medtronic Vascular (Ireland)
  • Sinomedical (China)
  • Lepu Medical (China)
  • BIOTRONIK (Germany)
Select User Access Type

Key Highlights of Report


Mar 2022 232 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drug-Eluting Stent Market Quantitative research analysis
Global Drug-Eluting Stent Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Drug-Eluting Stent Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Drug-Eluting Stent market is dominated by Players to generate healthy valuation by 2027.
Companies that are profiled in Global Drug-Eluting Stent Market are Terumo Corporation (Japan), B.Braun (Germany), Promed medical (United Arab Emirates), Boston Scientific (United States), Abbott Vascular (United States), Relisys Medical (India), Medtronic Vascular (Ireland), Sinomedical (China), Lepu Medical (China) and BIOTRONIK (Germany) etc.

Know More About Global Drug-Eluting Stent Market Report?

Have a Query? Click Here

Other Related Reports

Aortic Aneurysm Repair Devices Comprehensive Study by Type (Stent Grafts , Catheters , Others), Application (Abdominal Aortic Aneurysm Repair , Thoracic Aortic Aneurysm Repair), Anatomy (Traditional...
$ 3650
Hematology Comprehensive Study by Type (Hematology analyzers, Flow cytometers, Cell counters, Slide strainers, Coagulation analyzers, Hematology testing, Centrifuges, Hemoglobinometers DD, Others), A...
$ 3750
Handcycles Comprehensive Study by Type (Manual, Electric, Hybrid), Application (Wheelchair Hand Bikes, Sports Hand Bikes, Others) Players and Region - Global Market Outlook to 2027
$ 3500
Dental Veneers Comprehensive Study by Type (Composite Veneers, Conventional Porcelain Veneers, Minimal prep veneers, No Prep Veneers, Instant veneers, Others), Application (Hospital, Dental Clinic, O...
$ 3450
Artificial Discs Comprehensive Study by Type (Cervical Disc, Lumbar Disc), Application (Healthcare Industry), By Material Type (Metal-on-Polymer, Metal-on-Metal, Metal-on-Ceramic, Polymer-on-Ceramic)...
$ 3500
Micro Pump Comprehensive Study by Type (Mechanical Micropump {Diaphragm Micropumps, Peristaltic Micropumps}, Non-Mechanical Micropump {Valveless Micropumps, Capillary Pumps, Chemically Powered Pumps}...
$ 3750